Skip to main content
Premium Trial:

Request an Annual Quote

Digene Abandons Cytyc Merger, Citing FTC Anti-trust Threats

NEW YORK, July 1-Digene said today that it has terminated its merger with Cytyc, effective June 30.


Last week, the U.S. Federal Trade Commission said it would oppose the merger as a violation of anti-trust laws.


The two companies market screening tests for cervical cancer. Cytyc has the market-leading liquid Pap smear kit, and Digene offers the only FDA approved test for human papilloma virus, which is implicated in cervical cancer.


Cytyc announced its plans to acquire Digene in February 2002.


For further information, see the Digene website. ///issues/news//120495-1.html"

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.